GENFIT Reports First Half-Year 2023 Financial Results and : vimarsana.com

Cash, cash equivalents and current financial assets totaled €111.8 million as of June 30, 2023 Positive results in the pivotal Phase 3 ELATIVE® trial in...

Related Keywords

United Kingdom , France , Seal Rock , Massachusetts , United States , Zurich , Züsz , Switzerland , Paris , France General , Cambridge , Cambridgeshire , French , Sakina Sayah Jeanne , Pascal Prigent , Tom Huijbers , Sandra Silvestri , Steven Hildemann , Research Tax Credit , Financiers French Financial Markets Authority , Uncertainties Of The Company , Drug Administration , Euronext , Nasdaq , Hepatology Communications , Celloram Inc , Company Annual Shareholder Meeting , Patient Affairs , Research Translational Science , Board Of Directors The Company , Cash Flow Of The Group , Us Securities Exchange Commission , Head Of Global Medical Affairs , Service Transition Agreement , Group Cash , Transition Services Agreement , International Financial Reporting Standards , Research As , European Medicines Agency , Exchange Commission , Chronic Liver Failure , Investigational New Drug , Digestive Disease Week , Seal Rock Therapeutics , Reactive Oxygen Species , Hepatic Encephalopathy , Urea Cycle Disorders , Organic Acidemias , Inborn Errors , Non Invasive Test , Annual Shareholder Meeting , Executive Vice President , Chief Medical Officer , Global Medical Affairs , Patient Safety , Executive Vice President Research , Translational Science , European Medicines , Orphan Drug Designation , License Agreement , Transition Services , Consolidated Statement , Year Business , Financial Report , Registration Document , French Autorit , Des March , Consolidated Financial Results , Condensed Consolidated Statements , Financial Position , Cash Flow , Half Year Business , Cash Flows , Primary Biliary Cholangitis , Nasdaq Global Select Market , Private Securities Litigation Reform Act , French Financial Markets Authority , Paris Stock Exchange Gnft , Enfit Sa ,